Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissues25–27.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [26]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Research works printed but not linked: 1
- Walker, G.J. et al. .Mutations of the CDKN2/ p16INK4 gene in Australian melanoma kindreds. Hum. Molec. Genet. 4, 1845–1852 (1995).
Cited by
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,656
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521
Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
Arnold, M., Singh, D., Laversanne, M., Vignat, J., Vaccarella, S., Meheus, F., Cust, A. E., de Vries, E., Whiteman, D. C., & Bray, F. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.0160 · Cited by 1,484
Miller, A. J., & Mihm, M. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052166 · Cited by 1,339
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
“Finally, upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissue”
BackgroundThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Shain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Pavletich, N. P. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2640 · Cited by 744
“A Cdk-activator, cyclinD, is often found ampli®ed in breast cancer (Hunter & Pines, 1994; Sherr, 1996), and one of the Cdks, Cdk4, has been found mutated in melanoma (Wolfel et al., 1995; Zuo et al., 1996).”
BackgroundRane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
“The importance of the interaction between CDK4 and p16 INK4a became apparent with the identification of a mutation in CDK4 in patients with familial melanom”
BackgroundHereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 624
Schadendorf, D., Fisher, D. E., Garbe, C., Gershenwald, J. E., Grob, J.-J., Halpern, A., Herlyn, M., Marchetti, M. A., McArthur, G., Ribas, A., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.3 · Cited by 613
Human Cancer Syndromes: Clues to the Origin and Nature of Cancer
Fearon, E. R. (1997) · Science · doi:10.1126/science.278.5340.1043 · Cited by 605
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 588
“Germline mutations in cyclin-dependent kinase inhibitor 2A ( CDKN2A or p16) and, less common, mutations in cyclin-dependent kinase 4 ( CDK4 ) are the most frequent genetic abnormalities identified in these families (26-28).”
The INK4A/ARF locus and its two gene products.
Sharpless, N. E., & DePinho, R. A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80004-5 · Cited by 533
Russo, A. A., Tong, L., Lee, J.-O., Jeffrey, P. D., & Pavletich, N. P. (1998) · Nature · doi:10.1038/26155 · Cited by 524
The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
Bastian, B. C. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104658 · Cited by 513
“Approximately 2-‐‐3% of melanoma families have CDK4 mutations in the p16 binding domain (31), and a similar percentage has mutations that specifically disable p14/ARF(30, 32), which acts upstream of p53, by inhibiting its ubiquitinase mdm2.”
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
“Germline mutations of CDK4, an Rb-kinase that is inhibited by INK4A, have also been identified in melanoma-prone kindreds (Wolfel et al. 1995; Zuo et al. 1996; Soufir et al. 1998; Tsao et al. 1998; Molven et al. 2005).”
BackgroundGeographical Variation in the Penetrance of CDKN2A Mutations for Melanoma
Bishop, D. T. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.894 · Cited by 509
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“CDK4 Recurrent mutations of CDK4, which lead to cell cycle progression, have been reported in the germline of melanoma-prone families and in tumors (Wolfel et al. 1995; Zuo et al. 1996; Soufir et al. 1998; Tsao et al. 1998a; Molven et al. 2005).”
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
Yokoyama, S., Woods, S. L., Boyle, G. M., Aoude, L. G., MacGregor, S., Zismann, V., Gartside, M., Cust, A. E., Haq, R., Harland, M., et al. (2011) · Nature · doi:10.1038/nature10630 · Cited by 484
“Cases were drawn from (1) a population-based sample from Queensland, unselected for age at onset (Queensland study of Melanoma: Environment and Genetic Associations; Q-MEGA(36)) and (2) a population-based case–control family study of melanoma diagnosed before age 40 years, ascertained in Brisbane, Melbourne and Sydney…”
Self-citationTargeting CDK4/6 in patients with cancer
Hamilton, E., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 481
“CDK4 R24 mutations were first characterized in familial melanoma [19], and were identified in 2.”
Backgroundp16(MTS-1/CDKN2/INK4a) in Cancer Progression
Rocco, J. W., & Sidransky, D. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5149 · Cited by 470
“Additional support for this contention comes from the identification of mutations in cdk4 that inhibit p16 binding in 3 melanoma-prone families [55, 61, 62].”
BackgroundThe response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 456
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
Goldstein, A. M., Chan, M., Harland, M., Gillanders, E. M., Hayward, N. K., Avril, M.-F., Azizi, E., Bianchi-Scarra, G., Bishop, D. T., Bressac-de Paillerets, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0494 · Cited by 426
Self-citationHoughton, A. N., & Polsky, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00161-7 · Cited by 414
Skin cancer and new treatment perspectives: A review
Simões, M. C. F., Sousa, J. J. S., & Pais, A. A. C. C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.001 · Cited by 414
POT1 loss-of-function variants predispose to familial melanoma
Robles-Espinoza, C. D., Harland, M., Ramsay, A. J., Aoude, L. G., Quesada, V., Ding, Z., Pooley, K. A., Pritchard, A. L., Tiffen, J. C., Petljak, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2947 · Cited by 391
Self-citationCell cycle checkpoints and their inactivation in human cancer
Molinari, M. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00191.x · Cited by 388
“…in familial melanomas are found in the p16 gene (Hussussian et al. 1994; Kamb et al. 1994), as well as in cdk4, with the effect of affecting its binding to p16 (WoÈ lfel et al. 1995; Zuo et al. 1996), strongly suggesting that p16 also has an important role in preventing melanoma susceptibility.”
BackgroundSoufir, N. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.2.209 · Cited by 386
“Germline mutations segregate with the phenotype in melanoma kindreds (20, 21 ).”
BackgroundMethodInfluentialEpidemiology and Risk Factors of Melanoma
Carr, S., Smith, C., & Wernberg, J. (2020) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.005 · Cited by 360
The Tumor Suppressor Protein p16INK4a
SERRANO, M. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3824 · Cited by 346
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Borg, A., Sandberg, T., Nilsson, K., Johannsson, O., Klinker, M., Masback, A., Westerdahl, J., Olsson, H., & Ingvar, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1260 · Cited by 345
“lyzed without finding any evidence of mutation ( 24 ).”
BackgroundMethodInfluentialThe Concise Handbook of Family Cancer Syndromes
Lindor, N. M., Greene, M. H., & Program, M. F. C. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1039 · Cited by 339
Phosphorylation: Implications in Cancer
Singh, V., Ram, M., Kumar, R., Prasad, R., Roy, B. K., & Singh, K. K. (2017) · The Protein Journal · doi:10.1007/s10930-017-9696-z · Cited by 337
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
NCI DCEG Cancer Sequencing Working Group, Shi, J., Laboratory, N. D. C. G. R., French Familial Melanoma Study Group, Yang, X. R., Ballew, B., Rotunno, M., Calista, D., Fargnoli, M. C., Ghiorzo, P., et al. (2014) · Nature Genetics · doi:10.1038/ng.2941 · Cited by 331
Self-citationGenetics of melanoma predisposition
Hayward, N. K. (2003) · Oncogene · doi:10.1038/sj.onc.1206445 · Cited by 321
Self-citationLambert, J.-P., Ivosev, G., Couzens, A. L., Larsen, B., Taipale, M., Lin, Z.-Y., Zhong, Q., Lindquist, S., Vidal, M., Aebersold, R., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2702 · Cited by 318
“We elected to study a well-described series of sequence variants for the cyclin-dependent kinase CDK4 that have been identified in melanoma patients 25, 26 .”
MethodMC1R Genotype Modifies Risk of Melanoma in Families Segregating CDKN2A Mutations
Box, N. F., Duffy, D. L., Chen, W., Stark, M., Martin, N. G., Sturm, R. A., & Hayward, N. K. (2001) · The American Journal of Human Genetics · doi:10.1086/323412 · Cited by 310
“…shown to influence risk of melanoma: cyclin-dependent kinase inhibitor 2A (CDKN2A [MIM 600160]) (Hussussian et al. 1994; Kamb et al. 1994a), cyclindependent kinase 4 (CDK4 [MIM 123829]) (Zuo et al. 1996; Soufir et al. 1998), and the melanocortin-1 receptor (MC1R [MIM 155555]) (Palmer et al. 2000).”
BackgroundSelf-citationThe genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
“Affected individuals possess either an Arg24Cys or Arg24His mutatio”
BackgroundMcGarrity, T. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00890-4 · Cited by 303
Ichimura, K., Bondesson, M., Goike, H., Schmidt, E., Moshref, A., & Collins, V. P. (2000) · PubMed · Cited by 333
Blakytny, R., Jude, E. B., Martin Gibson, J., Boulton, A. J. M., & Ferguson, M. W. J. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200004)190:5<589::aid-path553>3.0.co;2-t · Cited by 160
Dei Tos, A. P., Doglioni, C., Piccinin, S., Sciot, R., Furlanetto, A., Boiocchi, M., Dal Cin, P., Maestro, R., Fletcher, C. D. M., & Tallini, G. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200004)190:5<531::aid-path579>3.0.co;2-w · Cited by 285
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Cyclin D1 is a candidate oncogene in cutaneous melanoma.
Sauter, E. R., Yeo, U. C., von Stemm, A., Zhu, W., Litwin, S., Tichansky, D. S., Pistritto, G., Nesbit, M., Pinkel, D., Herlyn, M., et al. (2002) · PubMed · Cited by 334
BRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
“Germline mutations in p16INK4a and CDK4 (CDK4R24C) are associated with familial melanoma (Hussussian et al., 1994; Zuo et al., 1996) and p16INK4a knockout mice treated with DMBA develop, among other tumours, melanoma (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundMelanoma etiology: where are we?
Tucker, M. A., & Goldstein, A. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206444 · Cited by 268
Self-citationStructural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
CDKN2A Mutations in Multiple Primary Melanomas
Monzon, J., Liu, L., Brill, H., Goldstein, A. M., Tucker, M. A., From, L., McLaughlin, J., Hogg, D., & Lassam, N. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381305 · Cited by 264
Self-citationThe INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 261
“The importance of p16INK4a has been further reinforced by finding of alterations that target its biochemical partners, that is, CDK4 point mutation that inhibits its binding to p16INK4a (Wolfel et al., 1995; Zuo et al., 1996) or CDK6 overexpression (Tang et al., 1999).”
BackgroundToward a Molecular Classification of Melanoma
Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 252
Molecular pathways: CDK4 inhibitors for cancer therapy
Dickson, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1551 · Cited by 245
Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles
Alonso, S. R., Ortiz, P., Pollán, M., Pérez-Gómez, B., Sánchez, L., Acuña, M. J., Pajares, R., Martínez-Tello, F. J., Hortelano, C. M., Piris, M. A., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63110-0 · Cited by 244
“These findings confirm previous observations in single G1/S markers in human malignant melanoma specimens6,7,9,22–24 and is supported by experimental observations in cell lines25,26 and animal models.27–30 Additionally, studies of familiar malignant melanoma have demonstrated mutations in genes regulating G1/S transit…”
BackgroundStructural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors
Jeffrey, P. D., Tong, L., & Pavletich, N. P. (2000) · Genes & Development · doi:10.1101/gad.851100 · Cited by 239
“…types (Kamb et al. 1994; Nobori et al. 1994; Hall and Peters 1996); cyclinD is often amplified in breast and prostate cancer (Hall and Peters 1996); mutations in Cdk4 that render it refractory to inhibition by INK4 have been identified in several cancer cases (Wolfel et al. 1995; Zuo et al. 1996).”
BackgroundZhu, G., Duffy, D. L., Eldridge, A., Grace, M., Mayne, C., O'Gorman, L., Aitken, J. F., Neale, M. C., Hayward, N. K., Green, A. C., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302494 · Cited by 238
“A second melanoma-predisposition gene, CDK4 (MIM 123829), has also been identified, but only three families with germline mutations have been documented (Zuo et al. 1996; Soufir et al. 1998).”
BackgroundSelf-citationHereditary melanoma: Update on syndromes and management
Soura, E., Eliades, P. J., Shannon, K., Stratigos, A. J., & Tsao, H. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.08.038 · Cited by 230
The molecular basis and clinical aspects of Peutz-Jeghers syndrome
Hemminki, A. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050329 · Cited by 230
Overcoming Immune Evasion in Melanoma
Eddy, K., & Chen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238984 · Cited by 222
Kefford, R. F., Newton Bishop, J. A., Bergman, W., & Tucker, M. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3245 · Cited by 224
Self-citationCyclin D-CDK4/6 functions in cancer
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.02.002 · Cited by 218
Mehenni, H., Gehrig, C., Nezu, J.-I., Oku, A., Shimane, M., Rossier, C., Guex, N., Blouin, J.-L., Scott, H. S., & Antonarakis, S. E. (1998) · The American Journal of Human Genetics · doi:10.1086/302159 · Cited by 219
“1997), and CDK4 (Zuo et al. 1996), are associated with predisposition to neoplasia when mutations result in activation of kinase activity.”
BackgroundRoads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling
Paluncic, J., Kovacevic, Z., Jansson, P. J., Kalinowski, D., Merlot, A. M., Huang, M. L.-H., Lok, H. C., Sahni, S., Lane, D. J. R., & Richardson, D. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.025 · Cited by 219
Xu, W., & Neckers, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2966 · Cited by 218
Pathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 217
“CDK4 mutations are associated with familial melanoma [116].”
Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample
Begg, C. B., Orlow, I., Hummer, A. J., Armstrong, B. K., Kricker, A., Marrett, L. D., Millikan, R. C., Gruber, S. B., Anton-Culver, H., Zanetti, R., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji312 · Cited by 213
Wide spectrum of tumors in knock‐in mice carrying a Cdk4 protein insensitive to INK4 inhibitors
Sotillo, R., Dubus, P., Martn, J., de la Cueva, E., Ortega, S., Malumbres, M., & Barbacid, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6637 · Cited by 208
Brotherton, D. H., Dhanaraj, V., Wick, S., Brizuela, L., Domaille, P. J., Volyanik, E., Xu, X., Parisini, E., Smith, B. O., Archer, S. J., et al. (1998) · Nature · doi:10.1038/26164 · Cited by 210
Franco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
“p16ink4a-mediated arrest is selectively bypassed by CDK4 mutations that disrupt the association with the inhibitor [24, 25].”
BackgroundYoung, R. J., Waldeck, K., Martin, C., Foo, J. H., Cameron, D. P., Kirby, L., Do, H., Mitchell, C., Cullinane, C., Liu, W., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12228 · Cited by 206
“…in CDK4 in the germline of humans leads to a 50-fold increase in the risk of developing melanoma (Hussussian et al., 1994; Kamb et al., 1994; Zuo et al., 1996) and this predisposition to melanoma is reflected in mouse models with loss of CDKN2A or activation of CDK4 (Hacker et al., 2006;…”
BackgroundSelf-citationTigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Melanoma genetics and the development of rational therapeutics
Chudnovsky, Y., Khavari, P. A., & Adams, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524808 · Cited by 204
Bauer, J., & Bastian, B. C. (2006) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2005.00055.x · Cited by 204
“Mutations in either p16 or CDK4 that disable this checkpoint result in a melanoma-prone condition (44).”
BackgroundUpdate in genetic susceptibility in melanoma.
Potrony, M., Bádenas, C., Aguilera, P., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., & Puig, S. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.08.11 · Cited by 198
“CDK4 was the second high risk melanoma susceptibility gene identified (49).”
BackgroundCDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Schettini, F., De Santo, I., Rea, C. G., De Placido, P., Formisano, L., Giuliano, M., Arpino, G., De Laurentiis, M., Puglisi, F., De Placido, S., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00608 · Cited by 201
CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma
Aitken, J., Welch, J., Duffy, D., Milligan, A., Green, A., Martin, N., & Hayward, N. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.446 · Cited by 200
“Predisposition to melanoma has also been linked to germline mutations within the CDK4 gene on chromosome 12, although inactivation of this locus appears to be a much rarer event, since only three such mutations have been documented to date (6, 15 ).”
BackgroundSelf-citationFitzGerald, M. G., Harkin, D. P., Silva-Arrieta, S., MacDonald, D. J., Lucchina, L. C., Unsal, H., O'Neill, E., Koh, J., Finkelstein, D. M., Isselbacher, K. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8541 · Cited by 200
Nathanson, K. L., Martin, A.-M., Wubbenhorst, B., Greshock, J., Letrero, R., D'Andrea, K., O'Day, S., Infante, J. R., Falchook, G. S., Arkenau, H.-T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 196
“Cell cycle regulatory proteins, such as p16, CKD4 and cyclin D1, also have been shown to play important roles in melanoma, and those genetic and genomic aberrations involving these also were specifically interrogated (36-38).”
BackgroundCDK4: A Key Player in the Cell Cycle, Development, and Cancer
Baker, S. J., & Reddy, E. P. (2012) · Genes & Cancer · doi:10.1177/1947601913478972 · Cited by 194
Androgen receptor gene and hormonal therapy failure of prostate cancer.
Koivisto, P. A., Kolmer, M., Visakorpi, T., & Kallioniemi, O. (1998) · Europe PMC (PubMed Central) · Cited by 219
Malignant melanoma: modern black plague and genetic black box
Chin, L., Merlino, G., & DePinho, R. A. (1998) · Genes & Development · doi:10.1101/gad.12.22.3467 · Cited by 194
“That the p16INK4a–CDK4 relationship is indeed relevant to melanoma is further supported by the identification of germline CDK4 mutations in two melanoma-prone families (Zuo et al. 1996; Soufir et al. 1998).”
BackgroundGenotype-Phenotype Relationships in U.S. Melanoma-Prone Families With CDKN2A and CDK4 Mutations
Goldstein, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.12.1006 · Cited by 192
Self-citationHocker, T. L., Singh, M. K., & Tsao, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.226 · Cited by 189
“In fact, both somatic and germline mutations in CDK4 have been detected in melanoma cell lines (Tsao et al., 1998a) and melanoma families (Zuo et al., 1996), respectively.”
BackgroundGlobal burden of cutaneous melanoma attributable to ultraviolet radiation in 2012
Arnold, M., de Vries, E., Whiteman, D. C., Jemal, A., Bray, F., Parkin, D. M., & Soerjomataram, I. (2018) · International Journal of Cancer · doi:10.1002/ijc.31527 · Cited by 183
“Mutations in the two main genes associated with melanoma (CDKN2A/p16 and CDK4) have been estimated to be responsible for 35–40% of familial melanomas.(20,21) Furthermore, variants causing loss of function of the human melanocortin 1 receptor gene (MC1R), which plays a crucial role in human skin pigmentation, have been…”
BackgroundCdk4 promotes adipogenesis through PPARγ activation
Abella, A., Dubus, P., Malumbres, M., Rane, S. G., Kiyokawa, H., Sicard, A., Vignon, F., Langin, D., Barbacid, M., & Fajas, L. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.003 · Cited by 172
“Cdk4R24C mice express a mutant cdk4 protein (R24C) which is not inhibited by the cdk inhibitor p16, rendering cdk4 hyperactive (Zuo et al., 1996).”
BackgroundMelanocortin-1 Receptor Variant R151C Modifies Melanoma Risk in Dutch Families with Melanoma
van der Velden, P. A., Sandkuijl, L. A., Bergman, W., Pavel, S., van Mourik, L., Frants, R. R., & Gruis, N. A. (2001) · The American Journal of Human Genetics · doi:10.1086/323411 · Cited by 173
“Identification of genes involved in melanoma skin cancer has been difficult, except in cases of very strong familial risk (Hussussian et al. 1994; Kamb et al. 1994b; Zuo et al. 1996).”
BackgroundThe genomic landscape of cutaneous melanoma
Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12459 · Cited by 172
“Similarly, the discovery of hotspot mutations in the p16-binding domain of CDK4 in melanoma families (Zuo et al., 1996) followed the discovery of similar mutations in melanoma tumors (W€olfel et al., 1995).”
BackgroundSelf-citationRane, S. G., Cosenza, S. C., Mettus, R. V., & Reddy, E. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.2.644-656.2002 · Cited by 167
“The importance of the CDK4 locus in human cancer was further emphasized upon identification of a germ line CDK4-Arg24Cys (R24C) mutation, which abolishes the ability of CDK4 to bind to p16, predisposing humans to hereditary melanoma (51, 53).”
BackgroundCyclins and CDKS in development and cancer: lessons from genetically modified mice
Santamaria, D. (2006) · Frontiers in Bioscience · doi:10.2741/1871 · Cited by 165
Invasive melanoma in Cdk4-targeted mice
Sotillo, R., García, J. F., Ortega, S., Martín, J., Dubus, P., Barbacid, M., & Malumbres, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241338598 · Cited by 164
Metadata
- Authors
- Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- Venue
- Nature Genetics
- Published
- 1996-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-99
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2051506850
- Cited by
- 818
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 24 · 2017: 36 · 2016: 24 · 2015: 27 · 2014: 32 · 2013: 30 · 2012: 19
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- CDK4, germline mutations, familial melanoma, cyclin-dependent kinases, cyclin D, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, hereditary melanoma, tumor-specific antigens
- MeSH terms
- Base Sequence, Carrier Proteins, Female, Humans, Male, Melanoma, Molecular Sequence Data, Pedigree, Proto-Oncogene Proteins, DNA Primers, Polymorphism, Single-Stranded Conformational, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.